Life sciences company Merck has seen an improvement in pulmonary arterial hypertension patients using its new signaling inhibitor sotatercept in a phase three clinical trial.
Merck sees success in new heart disease medication trial
Life sciences company Merck has seen an improvement in pulmonary arterial hypertension patients using its new signaling inhibitor sotatercept in a phase three clinical trial.